The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended ‘s Tagrisso (osimertinib) for approval in the European Union (EU) to treat individuals with locally advanced, unresectable non-small cell lung cancer (NSCLC). The therapy is for individuals whose tumours have specific epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, following no disease progression post-platinum-based chemoradiation therapy (CRT). The gold standard of business intelligence.
The CHMP’s positive opinion was influenced by outcomes from the Phase III LAURA study, which demonstrated that Tagrisso reduced disease progression or death risk by 84% versus placebo. Median progression-free survival (PFS) in patients treated with Tagrisso was 39.1 months, starkly contrasting to the 5.
6 months observed for the placebo arm. Although overall survival (OS) results are still maturing, the trial continues to evaluate OS as a secondary endpoint. Tagrisso’s safety profile in the LAURA trial aligned with its known characteristics, and no safety concerns were observed.
AstraZeneca Oncology research and development executive vice-president Susan Galbraith stated: “Today’s news reinforces Tagrisso as the backbone therapy in EGFR-mutated non-small cell lung cancer, meeting the critical unmet need for an effective targeted treatment option in the unresectable setting. Access the most comprehensive Company Profiles on the .
